School of Life Sciences, University of Warwick, Coventry, CV47AL, UK.
H3D, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7700, South Africa; Structural Genomics Consortium, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK.
J Mol Biol. 2019 Aug 23;431(18):3501-3519. doi: 10.1016/j.jmb.2019.07.010. Epub 2019 Jul 10.
Even with the emergence of antibiotic resistance, penicillin and the wider family of β-lactams have remained the single most important family of antibiotics. The periplasmic/extra-cytoplasmic targets of penicillin are a family of enzymes with a highly conserved catalytic activity involved in the final stage of bacterial cell wall (peptidoglycan) biosynthesis. Named after their ability to bind penicillin, rather than their catalytic activity, these key targets are called penicillin-binding proteins (PBPs). Resistance is predominantly mediated by reducing the target drug concentration via β-lactamases; however, naturally transformable bacteria have also acquired target-mediated resistance by inter-species recombination. Here we focus on structural based interpretations of amino acid alterations associated with the emergence of resistance within clinical isolates and include new PBP3 structures along with new, and improved, PBP-β-lactam co-structures.
即使出现了抗生素耐药性,青霉素和更广泛的β-内酰胺类抗生素仍然是最重要的抗生素家族。青霉素的周质/细胞外靶标是一组具有高度保守催化活性的酶,参与细菌细胞壁(肽聚糖)生物合成的最后阶段。这些关键靶标之所以被命名为青霉素结合蛋白(PBPs),是因为它们能够结合青霉素,而不是因为它们的催化活性。耐药性主要是通过降低β-内酰胺酶的靶药物浓度来介导的;然而,可自然转化的细菌也通过种间重组获得了靶介导的耐药性。在这里,我们专注于基于结构的解释与临床分离株中耐药性出现相关的氨基酸改变,并包括新的 PBP3 结构以及新的和改进的 PBP-β-内酰胺共结构。